ABSTRACT
[This retracts the article DOI: 10.5114/aoms.2019.86798.].
ABSTRACT
Issues caused by maxillofacial tumours involve not only dealing with tumours but also repairing jaw bone defects. In traditional tumour therapy, the systemic toxicity of chemotherapeutic drugs, invasive surgical resection, intractable tumour recurrence, and metastasis are major threats to the patients' lives in the clinic. Fortunately, biomaterial-based intervention can improve the efficiency of tumour treatment and decrease the possibility of recurrence and metastasis, suggesting new promising antitumour therapies. In addition, maxillofacial bone tissue defects caused by tumours and their treatment can negatively affect the physiological and psychological health of patients, and investment in treatment can result in a multitude of burdens to society. Biomaterials are promising options because they have good biocompatibility and bioactive properties for stimulation of bone regeneration. More interestingly, an integrated material regimen that combines tumour therapy with bone repair is a promising treatment option. Herein, we summarized traditional and biomaterial-mediated maxillofacial tumour treatments and analysed biomaterials for bone defect repair. Furthermore, we proposed a promising and superior design of dual-functional biomaterials for simultaneous tumour therapy and bone regeneration to provide a new strategy for managing maxillofacial tumours and improve the quality of life of patients in the future.
Subject(s)
Humans , Biocompatible Materials , Bone Regeneration , Bone and Bones , Quality of LifeABSTRACT
Objective:To analyze the effect of traditional Chinese medicine (TCM) non-drug therapy on all-cause mortality and 12-month readmission in patients with chronic heart failure.Methods:A total 824 patients aged (80±10) years with chronic heart failure admitted to 4 hospitals in Shanghai Pudong New Area from January 2016 to December 2019 were retrospectively enrolled. Propensity score match (PSM) method was used and 602 patients (301 pairs) were successively matched into TCM non-drug group (study group) and control group. The basic information, comorbidities, medication, laboratory test results, imaging findings, 12-month readmission and all-cause mortality after discharge were compared between two groups. Cox regression was used to analyze the influencing factors of adverse events in patients with chronic heart failure.Results:After PSM there were no significant differences in baseline variables between study group and control group ( P>0.05). The one-year survival probability of the study group was higher than that of the control group ( P=0.013). The adverse event incidence rate [43.52% ( n=131) vs. 53.82% ( n=162)], all-cause mortality [15.61% ( n=47) vs. 23.59% ( n=71)], 3-month readmission [10.96% ( n=33) vs. 17.61% ( n=53)], 6-month readmission [16.90% ( n=51) vs. 24.25% ( n=73s)], cardiac function classification, hs-CRP and NT-proBNP levels in study group were significantly lower than those in control group (all P<0.05). The Cox proportional risk model showed that old age ( RR=1.018, P<0.01), decreased cardiac function ( RR=2.200, P<0.01), diabetes ( RR=1.340, P=0.04), NT-proBNP≥7 900 ng/L( RR=1.557, P=0.01) were risk factors, while TCM non-drug therapy ( RR=0.768, P=0.04) was protective factor for the occurrence of adverse events. Conclusion:TCM non-drug therapy has a protective role for the occurrence of adverse events in patients with chronic heart failure. The use of TCM non-drug therapy should be advocated to improve the prognosis of patients, particularly at grassroots level.
ABSTRACT
INTRODUCTION: Owing to widespread roles of miRs, the dysregulation of their expression in human tissues has been linked with the development of several diseases such as cancer. The study was designed to investigate the role and therapeutic potential of miR-1179 in ovarian cancer. MATERIAL AND METHODS: Proliferation rate was monitored by MTT assay. Transfections were performed using Lipofectamine 2000 reagent. Cell cycle apoptosis was detected by AO/EB and annexin V/PI staining. Expressions analysis was carried out by qRT-PCR and western blotting. In vivo evaluation was carried out in xenografted mouse models. RESULTS: The results revealed that miR-1179 is considerably upregulated in ovarian cancer cell lines. Inhibition of miR-1179 triggers decrease in the viability via initiation of apoptotic cell death of ovarian PA-1 cancer cells. TargetScan analysis showed PTEN to be the main target of miR-1179 in PA-1 cells. Exploration of PTEN expression in ovarian cancer cell lines revealed up to 9-fold downregulation of PTEN. However, inhibition of miR-1179 in PA-1 cells resulted in upregulation of PTEN expression. In addition, overexpression of PTEN caused a reduction of PA-1 cell viability via induction of apoptotic cell death. However, silencing of miR-1179 could rescue the effects of miR-1179 inhibition on the proliferation of miR-1179. The miR-1179 suppression was accompanied by a significant decline in phosphorylation of PI3K and AKT expression in the PA-1 cells. The in vivo study showed that miR-1179 suppression inhibits the xenografted tumor growth. CONCLUSIONS: The results of this study indicate that miR-1179 may prove to be an important therapeutic target for ovarian cancer.
ABSTRACT
To analyze the potential limitations of hospital-level research projects management by summarizing its performance status from 2008 to 2011,including but not limited to lack of time for conducting research,insufficient financial funds,inadequate funding application,inadequate supervision.Thus,since 2014,our hospital has adopted some new measurements for projects management,including full-time research,hierarchical management,full mobilization,the establishment of reward and punishment measures,which significantly improved the quality of hospital-level research projects,and the rate of longitudinal follow-up project,research enthusiasm of medical staff,and sustainable development of hospital science and technology.
